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Pathological aggregation of the microtubule-associated protein tau and subsequent accumulation of neurofibrillary
tangles (NFTs) or other tau-containing inclusions are defining histopathological features of many neurodegenerative
diseases, which are collectively known as tauopathies. Due to conflicting results regarding a correlation between the
presence of NFTs and disease progression, the mechanism linking pathological tau aggregation with cell death is
poorly understood. An emerging view is that NFTs are not the toxic entity in tauopathies; rather, tau intermediates
between monomers and NFTs are pathogenic. Several proteins associated with neurodegenerative diseases, such as
β-amyloid (Aβ) and α-synuclein, have the tendency to form pore-like amyloid structures (annular protofibrils, APFs) that
mimic the membrane-disrupting properties of pore-forming protein toxins. The present study examined the similarities
of tau APFs with other tau amyloid species and showed for the first time the presence of tau APFs in brain tissue from
patients with progressive supranuclear palsy (PSP) and dementia with Lewy bodies (DLB), as well as in the P301L mouse
model, which overexpresses mutated tau. Furthermore, we found that APFs are preceded by tau oligomers and do not
go on to form NFTs, evading fibrillar fate. Collectively, our results demonstrate that in vivo APF formation depends on
mutations in tau, phosphorylation levels, and cell type. These findings establish the pathological significance of tau
APFs in vivo and highlight their suitability as therapeutic targets for several neurodegenerative tauopathies.
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The microtubule-associated protein tau plays important
cellular roles, including regulating microtubule assembly
and stability, axonal transport, and neurite outgrowth
[1]. Most of the biological functions of tau are modu-
lated by site-specific phosphorylation [2]. Tau self-
assembly, aggregation, and the accumulation of neuro-
fibrillary tangles (NFTs) are hallmarks of Alzheimer’s
disease (AD) and other neurodegenerative conditions
[3,4]. Although the importance of tau in AD and other
tauopathies is well established [5-7], it is unclear
whether NFTs are a primary neurotoxic agent. Most* Correspondence: rakayed@utmb.edu
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article, unless otherwise stated.research has focused on NFTs because of the reported
correlation between NFT levels in AD brain and disease
progression [8-10]; however, recent data suggest that sol-
uble pre-filamentous tau species may be the most toxic
and pathologically significant tau aggregates [11,12]. For
instance, cell death and synaptic lesions occur independ-
ently of NFT formation in htau mice expressing non-
mutant human tau [13,14]. Furthermore, hippocampal
synapse loss and microgliosis precede NFT formation in
the P301S transgenic mouse model (P301S Tg), which
overexpresses mutated tau [15]. Moreover, in a condi-
tional mouse model (rTg4510) expressing the P301L
htau mutant, soluble tau level was found to correlate
with neuronal loss and behavioral deficits to a greater
degree than NFT level [16,17].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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toxic species in many degenerative diseases in which the
accumulation of large fibrillar deposits may be inert, pro-
tective, or pathological by a different mechanism [18,19].
However, their structures, interrelationships with other
amyloid aggregates, and exact contribution to disease
pathogenesis are not entirely clear [20-23]. Amyloid-β
(Aβ), α-synuclein, and other amyloidogenic proteins form
annular protofibrils (APFs) in vitro; these pore-like struc-
tures have been observed in synthetic preparations of both
oligomers and fibrils [24,25]. The formation of pores by
Aβ and α-synuclein aggregates are accelerated when the
APFs are generated using proteins with mutations asso-
ciated with familial Alzheimer’s and Parkinson’s diseases,
respectively, suggesting that these mutated proteins are
more prone to pathogenic activity [26]. More importantly,
in addition to the generation of these structures from syn-
thetic peptides, APFs have been isolated from inclusions
in the brains of patients with multiple system atrophy
(MSA) [27] and AD [28,29]. Electron microscopy (EM)
and atomic force microscopy (AFM) of these structures
revealed that they vary in shape and size, lending support
to the concept of nonspecific pore formation and mem-
brane leakage. The amyloid pore hypothesis [30] suggests
that similar to bacterial pore-forming toxins [31-33],
amyloid oligomers/protofibrils induce cell death by dis-
rupting regulated membrane permeability, which disrupts
cellular ion and protein homeostasis. Membrane per-
meabilization is a common pathogenic effect of amyloid
oligomers [34], which are APF precursors. The off path-
way conversion of oligomers to APFs, which penetrate the
membrane, is an attractive explanation for this toxic effect
given the shared assembly state and morphological resem-
blance between APFs and bacterial pores.
Despite overwhelming evidence supporting amyloid
pore formation from biochemical, biophysical, and cell
culture experiments [26], tau pore formation has not
been shown in vitro or in vivo. The purpose of the
present study was to determine the relationship of tau
APFs with other tau amyloid species, such as small olig-
omers, and to determine if tau APFs are found in human
brain samples and the P301L Tg mouse model. Using
the well-characterized conformational antibody αAPF,
which specifically detects APFs independently of amino
acid sequence [28,29,31,35], we found that APFs are pre-
ceded by tau oligomers, are on a distinct pathway from
NFT formation, and that these pore-like structures are
present in human and P301L Tg mouse brain tissue. Fur-
thermore, our results indicate that in vivo APF forma-
tion depends on tau phosphorylation, the presence of
mutations, and cell type. These findings demonstrate the
pathological significance of tau APFs for several neuro-
degenerative tauopathies and highlight their suitability
as therapeutic targets for these diseases.Materials and methods
Preparation of Tau oligomers
Recombinant tau protein (tau-441 [2N4R], MW 45.9 kDa)
was expressed and purified as described previously [1,36].
It was treated with 8 M urea to obtain monomeric tau;
then it was dialyzed overnight against 1× PBS buffer
(pH 7.4) and adjusted to 1 mg/mL with PBS, and aliquots
of tau monomer (in PBS) were stored at −20°C. For oligo-
mer preparation, 300 μL tau stock (1 mg/mL) was added
to 700 μL 1× PBS, for a final concentration 0.3 mg/mL.
Aβ42 oligomers (7 μL, 0.3 mg/mL) were added to the
sample (seeds) and mixed by pipetting for 1 min. The
sample was then incubated at room temperature for 1 h
on an orbital shaker, and the resulting tau oligomers were
used to seed a new batch of tau. This procedure was re-
peated three times to eliminate the residual Aβ seeds. The
preparation and characterization of tau oligomers were
performed as described previously [37,38]. Paired helical
filament (PHF) tau fibrils from full-length recombinant
tau protein were prepared using heparin according to
well-established protocols [1,36].
Preparation and characterization of Tau APFs
A homogeneous population of pore-like tau APFs was
generated by using tau oligomers as the starting material.
First, 5% (v/v) hexane was added to a solution of oligo-
mers, and the sample was mixed with a vortex mixer for
1 min every 5 min for a total of 50 min. Then the samples
were dialyzed in water, using a molecular mass cut-off
membrane of 10 kDa. The morphologies of tau APF pre-
parations were characterized by EM and AFM and puri-
fied by size-exclusion chromatography using an LC-6
AD Shimadzu high-performance liquid chromatography
(HPLC) system (Shimadzu, Kyoto, Japan) fitted with a
Sephacryl S-500 HR (10 × 600 mm) column, (cat number:
17-0613-10; GE Healthcare Life Sciences, Little Chalfont,
UK). PBS (pH 7.4) was used as the mobile phase at a
1.5 mL/min flow rate. A gel filtration standard (51–1901;
Bio-Rad, Hercules, CA) was used for calibrations.
EM
For each sample, 2 μL was adsorbed onto 200-mesh
carbon and Formvar-coated grids, air-dried, and washed
for 1 min in distilled water. The samples were negatively
stained with 2% uranyl acetate (Ted Pella Inc., Redding,
CA) for 2 min and viewed with a Zeiss 10CR microscope
(80 kV; Carl Zeiss, Oberkochen, Germany).
AFM
The morphologies of synthetic tau APFs and immunopre-
cipitated structures was assessed by AFM by a non-contact
tapping method (ScanAsyst-Air, Bruker, Billerica, MA)
using a Multimode 8 AFM machine (Veeco, Plainview,
NY).
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For liposome preparation, 10 mg phosphatidylcholines
(Sigma, St. Louis, MO) was dissolved in 500 μL chloro-
form (20 mg/mL). The chloroform was evaporated under
a stream of nitrogen in the hood, the resulting film was
re-hydrated with 500 μL buffer (10 mM HEPES, 100 mM
NaCl, pH 7.4), and the solution was intensely vortexed for
3–5 min. Tau oligomers were dissolved to 66 μM in
H2O and incubated with liposomes in PBS (1/10 [v/v]
liposome/Tau oligomers) for 2 h at room temperature.
Human brain extracts
All postmortem brain tissue used were randomized.
Tissue from patients with progressive supranuclear palsy
(PSP) and control subjects were provided in frozen blocks
by the Brain Resource Center at Johns Hopkins University
(Baltimore, MD). Tissue cases were collected with patient
consent and handled under protocols approved by the
Johns Hopkins Institutional Review Board. PSP samples
were examined at the Division of Neuropathology at John
Hopkins University. For this study, PSP tissue from the
pons was utilized. The dementia with Lewy Bodies (DLB)
cases were obtained from the Oregon Brain Bank at
Oregon Health and Science University (OHSU, Portland,
OR). Tissue use conformed to OHSU Institutional Review
Board approved protocols. Neuropathologic assessment
conformed to National Institute on Aging-Reagan consen-
sus criteria.
Donor subjects were enrolled and clinically evaluated in
studies at the NIH-sponsored Layton Aging and AD Cen-
ter (ADC) at OHSU. Subjects were participants in brain
aging studies at the ADC and received annual neurological
and neuropsychological evaluations, with a clinical de-
mentia rating (CDR) assigned by an experienced clinician.
Cortex from DLB cases was used in the present study.
Each brain tissue sample was homogenized in PBS with a
protease inhibitor cocktail (catalog no. 11836145001;
Roche Applied Science, Indianapolis, IN), using a dilution
of brain: PBS of 1:3 (w/v). Samples were then centrifuged
at 10,000 rpm for 10 min at 4°C. The supernatants were
portioned into aliquots, snap-frozen, and stored at −80°C
until use [28].
Transgenic mouse model
P301L (JNPL3) mice (Taconic Farms) were used for our
experiments, including biochemical and immuno-
histochemistry (IHC) analyses. The JNPL3 mouse model
[39] expresses a frontotemporal lobar degeneration-
associated human mutant tau transgene (P301L). Mice
were housed at the University of Texas Medical
Branch (UTMB) animal care facility and were main-
tained according to USDA standards (12-h light/dark
cycle, food and water ad libitum), in accordance with
the Guide for the Care and Use of LaboratoryAnimals (National Institutes of Health, Bethesda,
MD). Animals were anesthetized according to UTMB
Institutional Animal Care and Use Committee-
approved procedures. Tissue was collected from 2-,
4-, 7-, 10-, and 12-month-old animals. Prior to eu-
thanasia, mice were deeply anesthetized and perfused
transcardially with 1× PBS prior to decapitation.
Animals were anesthetized according to IACUC-
approved procedures for animal sacrifice. After sacri-
fice, brains and spinal cords were dissected and
stored at −80°C. Mouse tissue was homogenized as
previously described for human samples [40].
Immunoprecipitation of APFs from human brain tissue
The characterization and specificity of the αAPF conform-
ation-specific antibody was published previously [31]. For
immunoprecipitation experiments, tosyl-activated mag-
netic Dynabeads (Dynal Biotech, Lafayette Hill, PA) were
coated with 11.25 μg αAPF antibody (2.6 mg/mL) and di-
luted in 0.1 M borate (pH 9.5) overnight at 37°C. Beads
were washed (0.2 M Tris, 0.1% bovine serum albumin
[BSA], pH 8.5) and then incubated with either DLB or
control patient brain homogenate with rotation at RT for
1 h. Beads were then washed three times with PBS and
eluted using 0.1 M glycine (pH 2.8). The pH of each eluted
fraction was adjusted using to pH 8.0 with 1 M Tris.
Finally, some fractions were applied to a nitrocellulose
membrane for dot blotting with the Tau-5 antibody
(Covance, Princeton, NJ). Other fractions were again co-
immunoprecipitated using spin columns (Cat# 26149,
Thermo Scientific, Waltham, MA) coated with Tau-5 anti-
body to ensure the presence of tau APFs for subsequent
AFM imaging.
Dot blot
Each sample (2 μl) was applied to a nitrocellulose mem-
brane, blocked with 10% nonfat milk in Tris-buffered
saline with Tween (TBS-T) overnight at 4°C, washed three
times for 5 min each with TBS-T, and incubated for 1 h at
RT with the anti-APF antibody αAPF (1:1000) for the syn-
thetic samples and the anti-tau antibody Tau-5 (1:5000)
for the immunoprecipitated samples. The membranes
were washed three times for 5 min each with TBS-T, incu-
bated with horseradish peroxidase (HRP)-conjugated anti-
rabbit IgG (Promega, Madison, WI) diluted 1:10000 in 3%
BSA/TBS-T, and incubated for 1 h at room temperature.
The blots were washed 3 times with TBS-T and developed
with an enhanced chemiluminescence kit from (RPN2132;
Amersham-Pharmacia/GE Healthcare Life Sciences, Little
Chalfont, UK).
Immunofluorescence
Paraffin-embedded brain sections from DLB, PSP, and
control subjects and JNPL3 mice were hydrated using
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tilled water. Then, the sections were heated by microwave
(750 watts) in target solution (Dako, Glostrup, Denmark)
twice for 4 min each. The tissues were washed in 1× PBS,
three times for 5 min each, and blocked for 45 min with
5% horse serum in PBS. The tissues were incubated with
rabbit anti-APF antibody αAPF antibody (1:350) over-
night. Then the sections were washed three times with
1× PBS for 10 min each. The sections were incubated with
the secondary antibody anti-rabbit Alexa Fluor 568 (1:700;
Invitrogen, Carlsbad, CA) for 60 min. Then, the sections
were washed three times with 1× PBS for 5 min each and
blocked again with 5% horse serum in PBS for 30 min.
The sections were then washed three times for 10 min
each time in PBS before incubation overnight with the
following antibodies: mouse anti-tau Tau-5 (1:1000),
anti-phospho tau (Ser202/Thr205) AT8 (1:1000, Thermo
Fisher), glial fibrillary acid protein (GFAP) (1:5000,
Covance), NeuN (1:3000, Chemicon International Inc.,
Temecula, CA), myelin oligodendrocyte glycoprotein
(MOG) (1:800; LifeSpan Biosciences, Seattle, WA) anti-Aβ
4G8 (1:800, Covance), and anti-α-synuclein 4D6 (1:700,
Covance). The next day, the sections were washed three
times in PBS for 10 min each before incubation with goat
anti-mouse IgG Alexa Fluor 488 (1:700, Invitrogen) for
1 h. Sections were washed and mounted in Vectashield
mounting medium with 4′,6-diamidino-2-phenylindole
(DAPI; Vector Laboratories, Burlingame, CA). The
sections were examined using a Bio-Rad Radiance 2100
confocal system (Bio-Rad, Hercules, CA) mounted on a
Nikon Eclipse E800 microscope (Nikon, Tokyo, Japan)
equipped with a CoolSnap-FX monochrome CCD camera
(Photometrics, Tucson, AZ) using a standard Nikon FITC,
TX Red, and DAPI filter set for Alexa Fluor 488 and 568
and DAPI, respectively.
APF IHC
Paraffin-embedded brain tissue sections from DLB, PSP,
and control subjects and JNPL3 mice were hydrated using
xylene, 100% ethanol, 95% ethanol, 80% ethanol, and dis-
tilled water. The hydrated sections were heated twice for
4 min each in target solution (Dako) using a microwave
oven (750 watts). Tissues were then washed in 1× PBS
three times for 5 min each and blocked for 10 min with
3% H2O2 in PBS. Tissues were then washed in 1× PBS
three times for 5 min each and blocked for 60 min with
5% horse serum in PBS. The tissues were incubated with
αAPF antibody (1:350) overnight. The sections were then
washed three times with 1× PBS for 10 min each, followed
by a 60-min incubation with the secondary biotinylated
anti-rabbit antibody (Pierce Biotechnology, Rockford, IL).
The sections were washed three times with 1× PBS for
5 min each. The sections were then incubated for 30 min
using an ABC kit and washed with 1× PBS three times for5 min each. Finally, the sections were incubated with
3,3′-diaminobenzidine (DAB) for 5 min.
Tau APF formation induced by myelin basic protein (MBP)
Purified human MBP (Chemicon International, Temecula,
CA) was resuspended in 20 mM sodium acetate and
100 mM sodium chloride (pH 4.0), dialyzed into PBS, and
stored at -80°C at 1 mg/mL. Tau oligomers (0.3 mg/mL)
were incubated at 37°C with rocking, either alone or with
1.56 μM MBP or 1.56 μM bovine lactalbumin. Control
samples containing Aβ oligomers and 1.56 μM MBP or
1.56 μM MBP in PBS were also included. At each time
point, 100 μL samples of each reaction were placed in a
96-well microplate in triplicate, and the amount of APF
formation was determined by enzyme-linked immuno-
sorbent assay (ELISA) using the αAPF antibody.
Direct ELISA
For ELISA, plates were coated with 100 μL sample using
0.1 M sodium bicarbonate (pH 9.6) as coating buffer,
followed by overnight incubation at 4°C and three washes
with TBS-T (0.01% Tween). Then, plates were blocked for
1 h at RT with 10% BSA (IgG-free TBS-T). The plates
were then washed three times with TBS-T before the pri-
mary antibody (αAPF, 1:500; T22, 1:1000; Tau5 1:1000)
was added and allowed to react for 1 h at RT. The plates
were then washed three times with TBS-T, and 100 μL
HRP-conjugated anti-rabbit IgG or anti-mouse IgG
(diluted 1:10,000 in 5% nonfat milk in TBS-T; Promega)
was added, followed by incubation for 1 h at RT. Finally,
plates were washed three times with TBS-T and developed
with 3,3,5,5-tetramethylbenzidine (TMB-1 component
substrate) from KPL (Gaithersburg, MD). The reaction
was stopped with 100 μL 1 M HCl, and samples were read
at 450 nm. Statistical analyses were based on a two-way
analyses of variance (ANOVAs), performed using Origin-8
software (Origin Lab, Northampton, MA).
Competitive ELISA
For competitive ELISA, plates were coated with 100 ng
tau oligomer (for T22) or APF (for αAPF) using 0.1 M so-
dium bicarbonate (pH 9.6) as the coating buffer, followed
by overnight incubation at 4°C. This protocol follows the
same directions indicated for the direct ELISA with the
exception that αAPF and T22 were pre-incubated with tau
monomers, oligomers, APFs, or fibrils for 45 min. During
the incubation, the amount of antibody was four times
greater than that of each tau species. Six samples were
run for each condition. For statistical analysis, two-way
ANOVA was performed using Origin-8 software.
Cell toxicity assay
Neuron viability was assessed using the MTT colorimetric
assay (Invitrogen) as previously described [31]. Briefly,
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with 2 μM tau oligomers, monomers, or APFs. After
incubation for 6 h at 37°C, the cells were assayed using
a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) toxicity assay kit (Tox-1) (Sigma) ac-
cording to the manufacturer’s directions. All measure-
ments were made in triplicate. Statistical analyses were
based on a two-way ANOVAs, which were performed
using Origin-8 software.Immunocytochemistry
SH-SY5Y cells were treated with 2 μM tau oligomers
or monomers for 6 h. Then, the cells on the coverslip
were fixed and permeabilized. The samples were
blocked for 1 h in 5% goat serum and incubated
overnight at 4°C with Tau-5 (1:1000). Sections were
then washed and incubated with an Alexa 488-conju-
gated goat anti-mouse antibody (1:700, Invitrogen) for
1 h at RT. Sections were then incubated overnight at
4°C with αAPF (1:350), then washed and incubated
with an Alexa 568-conjugated goat anti-mouse anti-
body (1:700). DAPI was used to stain the nuclei
(1:4000, Invitrogen). Sections were then washed for
30 min and coverslipped.Figure 1 In vitro formation of tau APFs. Tau oligomers used to prepare
also imaged by EM (c) and AFM (d). Tau APFs were recognized by the αAP
monomers, oligomers, or fibrils. Tau oligomers were recognized by T22, an
670 nm on HPLC revealed that tau APFs are formed by 10–12 tau monom
and for d 40 nm. White arrowheads indicate tau APF formation.Results
Tau oligomers form APFs in vitro
To determine whether tau forms APFs similarly to other
amyloid proteins, full-length human tau protein was
used to prepare tau oligomers as previously described
[37,38]. The presence of tau oligomers was confirmed by
both EM (Figure 1a) and AFM (Figure 1b) analysis.
Using tau oligomers as the starting material, APFs were
prepared with 5% hexane and characterized using EM
(Figure 1c) and AFM (Figure 1d). As we previously de-
monstrated, liposomes can catalyze the conversion of
oligomers to APFs under more physiologically relevant
conditions than treatment with 5% hexane [31]. When
liposomes were reconstituted with tau oligomers and in-
cubated for 2 h, APFs were detected by AFM (Additional
file 1: Figure S1a). The formation of tau APFs was also
confirmed by dot blot using the APF-specific antibody,
αAPF, which did not recognize tau monomers, oligo-
mers, or fibrils (Figure 1e). The selectivity of αAPF
for tau APFs was confirmed by competitive ELISA
(Additional file 1: Figure S1b). The conformational tau
antibody T22 was used to detect tau oligomers in dot-
blot (Figure 1e). The selectivity of T22 for tau oligomers
has been previously described [40]. Nevertheless, we
confirmed its selectivity for the oligomeric form of tautau APFs were characterized by EM (a) and AFM (b). Tau APFs were
F antibody on dot blot, which did not recognize recombinant tau
d all tau species were detected by Tau-5 (e). A distinct peak near
ers (f). The scale bars for a and b correspond to 100 nm, for c 20 nm,
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S1c and d). The HPLC analysis of tau APF prepared
in vitro showed a peak over 670 KDa, suggesting that
APFs range from decamers to dodecamers of tau mono-
mers (Figure 1f). We compared the toxicity of tau APFs
and oligomers and found that APFs are significantly less
toxic (Additional file 1: Figure S1e). As we previously re-
ported for Aβ and α-synuclein [31], tau APFs are less toxic
than the oligomers used to prepared them. Moreover,
whenever cells were treated with tau oligomers we ob-
served the formation of tau APFs whenever cells were
treated with tau oligomers, suggesting that one of the
toxic mechanisms of tau oligomers is APF formation
(Additional file 1: Figure S1f).
Tau APFs are present in DLB and PSP brain tissue and are
on a distinct pathway from hyperphosphorylated NFT
formation
The brain samples from patients with DLB and PSP and
age-matched controls used in this study are described in
Figure 2a. We analyzed DLB cases to study the presence
of tau APFs because although α-synuclein aggregates are
considered the primary pathological hallmark, a subset of
cases also exhibit tau aggregation in several cell types, in-
cluding neurons, astrocytes, and oligodendrocytes [41].
Similarly, PSP is mainly characterized by the deposition of
tau aggregates in neurons, astrocytes, and oligodendro-
cytes [42]. Our analysis allowed us to determine whichFigure 2 Tau APFs are present in DLB and PSP brain tissue. The age, g
group is summarized (a). APFs were detected in DLB cortex (top panel) and P
with αAPF (b). After immunoprecipitation using αAPF, tau annular structures
brain tissue (top, cortex; bottom, pons) by dot-blot analysis using Tau-5 antibo
tissue were visualized by AFM (d). Scale bar for HRP staining, 10 μm. Scale bastructural form of tau leads to APF formation. To investi-
gate the presence of pore-like structures in human DLB
and PSP brains, we used the αAPF antibody, which en-
abled us to distinguish APFs from other tau aggregates.
IHC of paraffin-embedded sections using the αAPF anti-
body and DAB revealed strong immunolabeling in both
DLB and PSP cases (Figure 2b). When IP was performed
using αAPF and probed with Tau-5 by dot blot, the pre-
sence of tau APFs was seen in all DLB and PSP disease
cases, with no reactivity seen in control brain samples
(Figure 2c). Subsequent examination of isolated tau APFs
by AFM revealed that these structures were similar to
those prepared from synthetic peptides (Figure 2d). Ad-
ditionally, αAPF immunoprecipitated from control tissues
did not pull down any APFs detectable by AFM (data not
shown). Immunoprecipitated APFs were more homoge-
neous in size (~15 nm in diameter) than synthetic APFs
(~5-20 nm in diameter). Although the immunoprecipi-
tated APFs were morphologically similar to the synthetic
peptides, they were not detected with Aβ and α-synuclein
antibodies (4G8 and 4D6, respectively) by dot blot (data
not shown), which suggests that APFs in DLB brain are
primarily composed of tau protein.
To confirm that the APFs detected in DLB and PSP
samples were indeed tau APFs, we performed double
immunofluorescence labeling using the αAPF antibody
and the tau-specific Tau-5 antibody. High levels of colo-
calization were seen in sections colabeled with αAPFender, post-mortem interval (PMI), and sampled brain regions in each
SP pons (bottom panel) by light field microscopy after immunolabeling
were detected in DLB and PSP cases but not in age-matched control
dy (c). Tau amyloid pores isolated from DLB (top) and PSP (bottom) brain
r for AFM images, 30 nm. White arrowheads indicate tau APFs.
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and Additional file 2: Figure S2a). However, in double
labeling using AT8, which recognizes tau phosphorylated
at Ser202/Thr205 (found in NFTs) [43], no colocaliza-
tion was for AT8 and αAPF (Figure 3b and Additional
file 2: Figure S2b). Therefore, it is likely that tau APFs
are not highly phosphorylated at epitopes Ser202/
Thr205 and arise from a different form of tau than that
found in NFTs.
Because tau APFs are best prepared from tau oligomers
in vitro, DLB brain sections were also analyzed for the
presence of tau oligomers colocalized with APFs by
immunofluorescent double labeling with αAPF and T22,
a polyclonal conformation-specific antibody against tau
oligomers [40]. Partial colocalization between tau oligo-
mers and APFs was seen (Additional file 3: Figure S3),
which is in agreement with the model suggesting that
oligomers form initially and proceed on a separate APF
formation pathway [28].
To determine whether APF formation is specific to cer-
tain cell types, DLB and PSP brain sections were examined
using immunofluorescent labeling with αAPF and GFAP,
MOG, or NeuN antibodies recognizing astrocytes, oligo-
dendrocytes, and neurons, respectively. Figure 4 shows
that tau APFs were found in oligodendrocytes and astro-
cytes in DLB brain, but not in neurons. Conversely, APFsFigure 3 Tau APFs are not phosphorylated at Ser202/Thr205. (a) Tau
Tau-5 (green) and αAPF (red) in DLB and PSP sections. (b) Double labeling
of cases, indicating that tau APFs are not largely phosphorylated at Ser202/were detected in all analyzed cell types in PSP brain
(Additional file 4: Figure S4). We did not identify any tau
pathology in the microglia in either the DLB or PSP tissue
(data not shown). It is well-known that DLB is characte-
rized by the presence of Lewy bodies and amyloid plaques
composed of aggregated α-synuclein and Aβ, respectively.
To determine if these amyloidogenic proteins also form
APFs in DLB, we performed double labeling with the
αAPF antibody and the anti-Aβ antibody 4G8 or the anti-
α-synuclein antibody 4D6. We did not observe any colo-
calization between αAPF and 4G8 or 4D6, suggesting
either that Aβ and α-synuclein do not form annular struc-
tures in DLB or that the epitopes recognize by 4G8 and
4D6 are not exposed in these structures (Additional file 5:
Figure S5).
Tau APFs are present in the JNPL3 mouse model
We next investigated whether APFs are present in the
JNPL3 mouse model of tauopathy [39], which expresses
the frontotemporal lobar degeneration-associated human
mutant tau transgene P301L under the prion promoter.
Mouse brain tissues were collected at different ages (2, 4,
7, 10, and 12 months) and biochemically analyzed for the
presence of tau APFs, which were found to increase in an
age-dependent fashion and peak at 10 months (Figure 5a).
This finding is in accordance with a publication thatAPFs were examined after double immunofluorescence labeling using
with AT8 (green) and αAPF (red) revealed lack of colocalization in all
Thr205. Scale bar, 10 μm.
Figure 4 Cell specificity of tau APFs in DLB. Double labeling with GFAP (green) and αAPF (red) demonstrated the presence of tau APFs in
astrocytes in DLB brains. Tau APFs in oligodendrocytes were demonstrated by double labeling with antibodies against MOG (green) and αAPF
(red). Tau APFs were not detected in neurons in DLB brains as shown by double labeling using NeuN (green) and αAPF (red). Scale bar, 10 μm.
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and behavioral disturbances at 10 months old [39]. The
decrease in tau APF levels in older mice (12 months)
could be explained by the cellular loss that occurs in the
model at that age. JNPL3 brain sections were then used in
αAPF IHC experiments, which revealed APFs in the
brainstem (Figure 5b). To verify that APF were comprised
of tau protein, JNPL3 brain sections were double labeled
with Tau-5 and αAPF. The results revealed that APFs
colocalized with Tau-5 (Figure 5c). Conversely, no coloca-
lization was observed following double labeling with AT8
and αAPF, demonstrating that tau APFs are not phospho-
rylated at epitopes Ser202/Thr205 (Figure 5c), similarly to
human brain sections from patients with DLB. Next, cell
specificity was examined by immunofluorescently labeling
mouse brain sections. Tau APFs were detected in oligo-
dendrocytes and neurons but not astrocytes (Figure 5d).
Because severe tau pathology has been described in
the JNPL3 spinal cord, we performed pathology studies
to determine the presence of tau annular structures in
this region. APFs detected were highly colocalized with
Tau-5 (Figure 5e), affirming that tau APFs are present in
the spinal cord. Double labeling with AT8 and αAPF re-
vealed that tau APFs are sporadically phosphorylated atepitopes Ser202/Thr205 (Figure 5e). The annular struc-
tures detected with AT8 were identified as axonal sphe-
roids, which may indicate disrupted axonal transport
and degeneration. The presence of tau APFs phosphory-
lated at Ser202/Thr205 in the spinal cord suggests that
annular structure formation occurs by a different me-
chanism than in the brain. To clarify which cell types
are affected in the spinal cord, we performed double la-
beling with αAPF and GFAP, NeuN, or MOG (Figure 5f ).
Tau APFs were detected in all cell types analyzed (oligo-
dendrocytes, neurons, and astrocytes), demonstrating
that these tau structures are more prone to form in the
spinal cord than in the brain.
Because tau APFs were mainly detected in oligodendro-
cytes in DLB and PSP patient brains and JNPL3 mouse
brain and spinal cord, we studied the ability of MBP to
induce the formation of APFs from tau oligomers. We
incubated tau oligomers with MBP and performed kinetic
analyses of APF formation with ELISAs using the αAPF
antibody (Additional file 6: Figure S6a). The results show
that mixing MBP with tau oligomers induces tau APF for-
mation as early as 30 min after starting the incubation.
Samples were also analyzed by AFM, which detected APFs
after 3 h of incubation (Additional file 6: Figure S6b). No
Figure 5 Tau APFs in the brain and spinal cord of the P301L tauopathy mouse model. (a) Tau APFs were detected by dot blots of brain
tissue from P301L mice probed with αAPF, with a peak at 10 months. (b) Tau APFs were detected in the brainstem of P301L mice with αAPF IHC.
(c) Tau APFs were also detected in P301L brains by double immunofluorescence using Tau-5 (green) and αAPF (red). Double labeling using AT8
(green) and αAPF (red) revealed a lack of colocalization, indicating that tau APFs were not phosphorylated at epitopes Ser202/Thr205 or that the
phospho epitopes are inaccessible. (d) Tau APFs in oligodendrocytes were confirmed by double labeling using MOG and αAPF. Tau APFs were
detected in the neurons of P301L mouse brain by double labeling with NeuN and αAPF, but double labeling with GFAP and αAPF demonstrated that
tau APFs were not found in astrocytes in P301L brains. (e) Tau APFs were detected in 10-month-old P301L spinal cord by double immunofluorescence
using Tau-5 (green) and αAPF (red). A low level of colocalization indicates that tau APFs are sporadically phosphorylated at epitopes Ser202/Thr205,
specifically in axonal spheroids in the spinal cord. (f) Double labeling with GFAP (green) and αAPF (red) demonstrates that tau APFs are formed in
astrocytes in P301L spinal cord. Tau APFs were also detected in neurons in P301L spinal cord. This was confirmed by double staining with NeuN
(green) and αAPF (red). The location of tau APFs in oligodendrocytes was confirmed by double labeling for MOG (green) and αAPF (red). The scale
bars for HRP (b) and IF (c-f) corresponded to 10 and 20 μm, respectively. White arrows indicated colocalization.
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MBP or tau was mixed with lactalbumin, suggesting that
this MBP-triggered process is specific for tau.
Discussion
Amyloid-related diseases may be characterized by a com-
mon mechanism of aggregation and cytotoxicity that critic-
ally involves membrane permeabilization [30,44,45].
Several models have hypothesized how oligomers might
disrupt cellular membranes, including transmembrane
oligomeric pore structures reminiscent of those of pore-
forming toxins [30,45], nonspecific binding of amyloidoligomers to the membrane surface [44,46], and detergent-
like membrane dissolution by amyloid fibrils growing on
the membrane surface [47]. As we previously reported for
Aβ [28], tau oligomers are both the intermediates of tau
fibril aggregation and the precursors of APF formation.
The findings of the present study suggest that in vitro and
in vivo tau APFs form via a pathway that is independent of
NFT formation (Figure 6a). The mechanism of membrane-
catalyzed conformational conversion of oligomers into an-
nular pores is not yet well understood. It is possible that
following an initial electrostatic interaction with the mem-
brane, individual spherical oligomers are drawn into the
Figure 6 Working model for tau APF formation. (a) In the proposed mechanism for tau APF formation, tau associated with microtubules (MT)
must be released to create an available pool of free soluble tau. Tau then undergoes a conformational change that facilitates misfolding and the
formation of oligomers, which can then either proceed along the pathway to form paired helical filaments (PHF) that aggregate and form neurofibrillary
tangles (NFTs) or align to form spherical, pore-like structures (APFs). (b) At the cellular level, the formation of these annular structures could occur
whenever oligomers are associated in a suitable environment, such as the cell, nuclear, or organelle membranes, allowing for toxic, nonspecific ion
leakage.
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ational transition to expose their hydrophobic segments
and assemble into pore-like structures [21,48-51]. A similar
membrane-catalyzed assembly has been proposed for the
pore-forming toxins, in which the stepwise binding of the
toxin to the membrane, membrane- catalyzed confor-
mational change, and toxin oligomerization lead to the for-
mation of membrane-embedded pores [32].
To our knowledge, this is the first study to describe the
formation of tau APFs both in vitro and in vivo. However,
the association of tau with the plasma membrane has been
extensively described [52-54]. The authors of one study
demonstrated a phosphorylation-dependent dynamic as-
sociation between tau and the neuronal membrane [53].
Specifically, they showed that that dephosphorylation of
tau at epitopes (including Ser202/Thr205) results in its
translocation from the cytosol to the membrane, and this
process is dependent on a direct interaction between Fyn
and tau via the fyn-SH3 domain [55]. The function
of plasma membrane-associated tau remains unclear;
nevertheless, accumulating evidence suggests that the
interaction between tau and Fyn might be crucial for the
tau-mediated regulation of intracellular signaling [56].
Bhaskar and colleagues demonstrated that the affinity bet-
ween Fyn and tau was increased 25–45 fold by the tau
P301L mutation [55], which is the same mutation in the
JNPL3 mouse model used in our study. This could explain
the high amount of tau APFs detected in the JNPL3
model. Moreover, a recent study by Flach et al. revealed
that tau oligomers impair artificial membrane integrity
and cellular viability [57]. The authors showed that tau
oligomers produce a deleterious effect on membrane
permeabilization in SH-SY5Y cells. Furthermore, they
corroborated these observations with a vesicle per-
meabilization assay, where they measured leakage of thefluorescent dye ANTS out of phospholipid vesicles. The
authors observed a more pronounced effect in vesicles
treated with tau oligomers rather than monomers or
fibrils, suggesting that the cellular membrane might be a
primary target of tau oligomers. Collectively, the existing
evidence suggests that tau oligomers that are not phos-
phorylated at Ser202/Thr204 [40] could interact with Fyn
and be taken into the plasma membrane given a suitable
environment for tau APF formation. On the other hand, if
tau oligomers continue their aggregation process and be-
come phosphorylated at Ser202/Thr205, no interaction
with Fyn will occur, leading to NFT formation. Further
studies are necessary to establish the direct relationship
between Fyn and tau APF formation.
EM analysis of pores isolated from human brains with
AD and MSA inclusions revealed that they are indeed
composed of individual spherical oligomers that vary in
shape and size, lending support to the notion of non-
specific pore formation and membrane leakage [28,58].
Nevertheless, other laboratories reported the ability of
oligomers to form calcium channels in lipid bilayers and
neuronal cells [59-61]. A study from Jang et al. [62] re-
ported the ability of Aβ oligomers to assemble into pores
with single-channel conductance that allow calcium up-
take. Our results do not rule out the possibility of chan-
nel activity by tau pores. Either through the formation of
channels or through nonspecific ion leakage, tau oligo-
mers and APFs may lead to an influx of calcium and its
subsequent dysregulation. NMDA receptor antagonists,
such as memantine, block extrasynaptic calcium release
and have been shown to be neuroprotective [63]. Re-
cently, Kokubo et al. [35] reported that APFs were found
not only on plasma membranes but also on vesicles in-
side of cell processes by immuno-EM using an αAPF
antibody in transgenic mice expressing a mutant form of
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several cellular environments can promote the formation
of these annular structures. This last point was confirmed
by our results showing tau APFs in different subcellular
localizations, indicating that tau APFs are formed in both
plasma and organelle membranes (Figure 6b). The present
study also demonstrated that tau APFs are located in dif-
ferent cell types in DLB and PSP brains and JPNL3 brain
sections and spinal cord. It is possible that the cell type in
which tau APFs are formed will condition the clinical
symptoms in different tauopathies or behavioral impair-
ments in tau transgenic mouse models. Nevertheless, it is
important to consider that P301L tau in the JNPL3 mouse
model is expressed under the prion promoter, which is
mainly expressed in neurons but also in oligodendrocytes
and astrocytes. This is extremely important considering
that it is well-known that tau is not expressed in astro-
cytes, suggesting different sources of tau in the formation
of APFs in human tauopathies and the JNPL3 mouse
model. While the presence of tau APFs in JPNL3 astro-
cytes could merely be due to the expression of tau in these
cells, in the case of human tauopathies, the presence of
these tau structures would be better explained by the in-
ternalization of exogenous tau into the astrocytes, which
was previously suggested for Aβ and α-synuclein [29,65].
We observed tau pores in oligodendrocytes in all of the
studied samples. Several publications have demonstrated
the relevance of tau aggregation in oligodendrocytes in dif-
ferent tauopathies and many mouse models [39,42,66-68].
Furthermore, a study by Klein et al. showed that Fyn inter-
acts with tau in oligodendrocytes to promote myelination
[69]. Specifically, the authors demonstrated that Fyn acti-
vation in lipid raft microdomains leads to an increased
binding to tau and its recruitment to the area of contact
with the neuronal axon. This concept is also supported by
our in vitro data showing that MBP induces the formation
of tau APFs, suggesting that areas rich in MBP are more
prone to induce tau APF formation. The ability of MBP to
induce the formation of annular structures from amyloid
oligomers appears to be sequence-specific and is not a
general mechanism for all amyloidogenic proteins (e.g.,
Aβ), which fails to form APFs in the presence of MBP.
Nevertheless, previous studies have demonstrated that
MBP binds to Aβ and inhibits amyloid fibril formation
[70-72], suggesting that MBP does have some influence on
the aggregation process of other amyloidogenic proteins.
Our novel findings linking tau oligomers with tau APFs
enhance the understanding of amyloid oligomer-mediated
neurodegeneration in vivo and underscore the complexity
of tau structures in several tauopathies. Understanding the
fundamentals of in vivo tau pore formation and properties
is critical for establishing potential links between tau ag-
gregation and the mechanisms of cellular toxicity that
occur during neurodegenerative disease progression. Still,additional research should examine the nature of these
tau pores and determine whether they represent single
channels or nonspecific pores and clarify their relationship
with Fyn.
Additional files
Additional file 1: Figure S1. Tau oligomers for APFs in vitro and in cell
culture. (a) AFM was performed to observe how liposomes catalyze the
conversion of oligomers to APFs. White arrowheads indicate tau APF
formation. Scale bar, 10 nm. (b) Competitive ELISA showed that pre-
incubation αAPF with tau APFs (4:1) led to the loss of the antibody’s ability
to detect coated tau APFs. However, no effect was observed in the
selectivity of αAPF for coated tau APFs when the antibody was pre-
incubated with monomeric, oligomeric, or fibrillar tau (4:1). (c) Direct ELISA
showed that T22 exclusively recognizes tau oligomers but not monomers,
APFs, or fibrils. Tau-5 signals were equivalent when plates were coated with
equal amounts of various tau species. (d) Competitive ELISA showed that
when pre-incubation of T22 with tau oligomers (4:1) resulted in the loss of
the antibody’s ability to detect coated tau oligomers. No effect on T22
selectivity for coated tau oligomers was observed when the antibody was
pre-incubated with monomeric tau, APFs, or fibrillar tau (4:1). (e) Cytotoxicity
was measured in SH-SY5Y cells using the MTT assay with 2 μM tau monomer,
oligomer, APF or fibril. Tau oligomers were significantly more toxic than tau
APFs. (f) Double immunofluorescence using Tau-5 (green) and αAPF (red)
revealed tau APF formation when cells were treated with tau oligomers.
White arrowheads indicate APFs. Scale bar, 10 μm. n = 6 per condition in b-e,
*p < 0.05 and **p < 0.001.
Additional file 2: Figure S2. Tau APFs are not phosphorylated at Ser202/
Thr205. (a) Tau APFs were detected by double immunofluorescence using
Tau-5 (green) and αAPF (red) antibodies in DLB and PSP sections. (b) In
double labeling with AT8 (green) and αAPF (red), the lack of colocalization
in all cases indicates that tau APFs are largely unphosphorylated at epitopes
Ser202/Thr205. Scale bar, 10 μm.
Additional file 3: Figure S3. Interaction between oligomers and APFs
in DLB brains. Double labeling with the anti-tau oligomer antibody T22
(green) and the αAPF antibody (red) demonstrates an interaction
between tau oligomers and APFs in vivo.
Additional file 4: Figure S4. Cell specificity of tau APFs in PSP. Double
labeling with GFAP (green) and αAPF (red) antibodies demonstrates that
tau APFs are found in astrocytes in DLB brains. The presence of tau APFs
in oligodendrocytes was confirmed by double labeling using MOG
(green) and αAPF (red) antibodies. Tau APFs were also detected in
neurons in DLB brains. This was confirmed by double staining using
NeuN (green) and αAPF (red). Scale bar 10 μm.
Additional file 5: Figure S5. Annular protofibrils from Aβ and α-synuclein
were not detected in DLB cases. The lack of colocalization between αAPF
(red) and 4G8 (green; top panels) or 4D6 (green; bottom panels) labeling
suggests that Aβ APFs and α-synuclein APFs, respectively, are not present in
DLB brains.
Additional file 6: Figure S6. MBP induce tau APF formation. (a) Incubation
of tau oligomers with MBP induced the formation of tau APFs as measured
by ELISA using the αAPF antibody. MBP did not induce the formation of Aβ
APFs from Aβ oligomers. Incubation of tau oligomers with albumin also
failed to induce tau APF formation. (b) Tau APFs formed due to the
interaction between oligomers and MBP were visualized by AFM. Scale bar,
5 nm.
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